Pay in 4 interest-free payments of $6.06 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Weight Loss and Metabolic Benefits: Obesity is a major risk factor for cardiovascular disease
SURPASS-CVOT is a phase 3 study enrolled approximately 13,000 patients at least 40 years of age and have a diagnosis of type 2 diabetes, confirmed atherosclerotic cardiovascular disease, HbA1c 7.0% to 10.5% and a body mass index (BMI) 25 kilograms per meter squared (kg/m 2 )
Next generation of obesity drugs - combination By the time Novo Nordisk's scientists had unlocked the potential of GLP-1 for obesity, a number of other researchers elsewhere were beginning to also explore its potential
Semaglutide, the active ingredient in medications like Wegovy, Ozempic, and Rybelsus, works by mimicking a naturally occurring hormone in your body called glucagon-like peptide-1 (GLP-1)
US$ 20.73
US$ 23.48
US$ 22.17
US$ 24.13
US$ 25.58
US$ 20.61
US$ 26.66
US$ 25.88
US$ 26.58
